New pill tested for tough cancers like mesothelioma

NCT ID NCT04857372

Summary

This early-stage study is testing a new oral medication called IAG933 in adults with advanced cancers, including mesothelioma, that have specific genetic changes. The main goals are to find a safe dose and see how well the body handles the drug. Researchers will also look for early signs that the drug might help control tumor growth in patients who have run out of standard treatment options.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030 4009, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Novartis Investigative Site

    Melbourne, Victoria, 3000, Australia

  • Novartis Investigative Site

    Montreal, Quebec, H2W 1T8, Canada

  • Novartis Investigative Site

    Villejuif, 94800, France

  • Novartis Investigative Site

    Essen, 45147, Germany

  • Novartis Investigative Site

    Milan, MI, 20133, Italy

  • Novartis Investigative Site

    Rozzano, MI, 20089, Italy

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035, Spain

  • Novartis Investigative Site

    Zurich, 8091, Switzerland

  • Novartis Investigative Site

    Manchester, M20 2BX, United Kingdom

  • Uni of Chi Medi Ctr Hema and Onco

    Chicago, Illinois, 60637, United States

  • University of California LA

    Los Angeles, California, 90095, United States

Conditions

Explore the condition pages connected to this study.